Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Chief Executive Albert Bourla told analysts he is hopeful about finding a solution in response to President Trump’s demands.

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

U.S. stocks closed rallied on Friday, with the Nasdaq Composite (COMP:IND) securing another back-to-back record, even as ...

On the company’s Q2 earning call, Pfizer (PFE) noted that the company’s guidance “absorbs the impact of the currently imposed ...

As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing ...

Pfizer's oncology pipeline looks promising. The company's newer approvals could make significant progress. And its efforts to ...

Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...

Albert Bourla confirmed that he called President Donald Trump after receiving a letter asking Pfizer and a clutch of other ...

President Donald Trump said his administration is prepared to increase the tariffs it plans to impose on pharmaceuticals up ...

Pfizer said the new forecast includes a one-time charge of 20 cents per share related to its recent licensing deal with China ...

Pharmaceuticals account for the bulk of Irish exports to the US and any change, or even uncertainty, on tariffs poses major ...